 | • レポートコード：MRC308GR11457 • 出版社/出版日：GlobalInfoResearch / 2023年8月12日 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（2-3営業日） • 産業分類：医薬品＆ヘルスケア |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Corporate User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
GlobalInfoResearchの最新の調査によると、世界の膜性腎症治療の市場規模は2022年のxxx米ドルから2029年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を考慮しながら市場規模を推計しました。
このレポートは、世界の膜性腎症治療市場に関する詳細かつ包括的な分析の結果です。定量的分析と定性的分析データが、メーカー別、地域別、国別、種類別、用途別に記載されています。
市場は常に変化しているため、本レポートでは、競争、需要と供給の傾向、および多くの市場にわたる需要の変化に影響する主要な要因を調査しました。主要な競合他社の企業概要と製品例、および2023年の市場シェア予測も記載しました。
本レポートの主な目的は次のとおりです。
– 世界および主要国の市場機会の規模を決定するため
– 膜性腎症治療の成長可能性を評価するため
– 各製品および最終用途市場の将来の成長を予測するため
– 市場に影響を与える競争要因を評価するため
膜性腎症治療市場は種類と用途によって区分されます。2018年～2029年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。
種類別セグメント
・アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他
用途別セグメント
・病院薬局、小売薬局、オンライン薬局
主要な市場プレーヤー
・Abbie. Inc.、Astrazeneca Plc.、F. Hoffman- La Roche Ltd.、Fibrogen、Allergan Plc.、Amgen Inc、Pfizer Inc.、Novartis. AG.、Apotex Inc.、Teva Pharma Industries Ltd.
地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）
本調査レポートの内容は計15章あります。
・第1章では、膜性腎症治療製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な膜性腎症治療メーカーの企業概要、2019年～2022年までの膜性腎症治療の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な膜性腎症治療メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2018年～2029年までの地域別膜性腎症治療の販売量、売上、成長性を示しています。
・第5、6章では、2018年～2029年までの膜性腎症治療の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2018年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2029年までの主要地域での膜性腎症治療市場予測を収録しています。
・第12章では、市場力学、成長要因、阻害要因、トレンド、ポーターズファイブフォース分析、新型コロナウイルス感染症とロシア・ウクライナ戦争の影響を掲載しています。
・第13章では、主要な原材料、主要なサプライヤー、および膜性腎症治療の産業チェーンを掲載しています。
・第14、15章では、膜性腎症治療の販売チャネル、販売業者、顧客、調査結果について説明します。
***** 目次(一部) *****
・市場概要
– 膜性腎症治療の概要
– 種類別分析（2018年vs2022年vs2029年）：アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他
– 用途別分析（2018年vs2022年vs2029年）：病院薬局、小売薬局、オンライン薬局
– 世界の膜性腎症治療市場規模・予測
– 世界の膜性腎症治療生産能力分析
– 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
– Abbie. Inc.、Astrazeneca Plc.、F. Hoffman- La Roche Ltd.、Fibrogen、Allergan Plc.、Amgen Inc、Pfizer Inc.、Novartis. AG.、Apotex Inc.、Teva Pharma Industries Ltd.
・メーカー別市場シェア・市場集中度
・地域別市場分析2018年-2029年
・種類別分析2018年-2029年：アルキル化剤、シクロホスファミド、クロランブシル、環状ペプチド、タクロリムス、ミコフェノール酸モフェチル、その他
・用途別分析2018年-2029年：病院薬局、小売薬局、オンライン薬局
・膜性腎症治療の北米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：アメリカ、カナダ、メキシコなど
・膜性腎症治療のヨーロッパ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・膜性腎症治療のアジア市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・膜性腎症治療の南米市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：ブラジル、アルゼンチンなど
・膜性腎症治療の中東・アフリカ市場
– 種類別市場規模2018年-2029年
– 用途別市場規模2018年-2029年
– 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・市場力学（成長要因、阻害要因、トレンド、ポーターズファイブフォース分析）
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論
1 Market Overview
1.1 Product Overview and Scope of Membranous Nephropathy Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Membranous Nephropathy Treatment Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Alkylating Agents
1.3.3 Cyclophosphamide
1.3.4 Chlorambucil
1.3.5 Cyclic Peptides
1.3.6 Tacrolimus
1.3.7 MycophenolateMofetil
1.3.8 Others
1.4 Market Analysis by Application
1.4.1 Overview: Global Membranous Nephropathy Treatment Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital pharmacy
1.4.3 Retail pharmacy
1.4.4 Online Pharmacy
1.5 Global Membranous Nephropathy Treatment Market Size & Forecast
1.5.1 Global Membranous Nephropathy Treatment Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Membranous Nephropathy Treatment Sales Quantity (2018-2029)
1.5.3 Global Membranous Nephropathy Treatment Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Abbie. Inc.
2.1.1 Abbie. Inc. Details
2.1.2 Abbie. Inc. Major Business
2.1.3 Abbie. Inc. Membranous Nephropathy Treatment Product and Services
2.1.4 Abbie. Inc. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Abbie. Inc. Recent Developments/Updates
2.2 Astrazeneca Plc.
2.2.1 Astrazeneca Plc. Details
2.2.2 Astrazeneca Plc. Major Business
2.2.3 Astrazeneca Plc. Membranous Nephropathy Treatment Product and Services
2.2.4 Astrazeneca Plc. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Astrazeneca Plc. Recent Developments/Updates
2.3 F. Hoffman- La Roche Ltd.
2.3.1 F. Hoffman- La Roche Ltd. Details
2.3.2 F. Hoffman- La Roche Ltd. Major Business
2.3.3 F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Product and Services
2.3.4 F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 F. Hoffman- La Roche Ltd. Recent Developments/Updates
2.4 Fibrogen
2.4.1 Fibrogen Details
2.4.2 Fibrogen Major Business
2.4.3 Fibrogen Membranous Nephropathy Treatment Product and Services
2.4.4 Fibrogen Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Fibrogen Recent Developments/Updates
2.5 Allergan Plc.
2.5.1 Allergan Plc. Details
2.5.2 Allergan Plc. Major Business
2.5.3 Allergan Plc. Membranous Nephropathy Treatment Product and Services
2.5.4 Allergan Plc. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Allergan Plc. Recent Developments/Updates
2.6 Amgen Inc
2.6.1 Amgen Inc Details
2.6.2 Amgen Inc Major Business
2.6.3 Amgen Inc Membranous Nephropathy Treatment Product and Services
2.6.4 Amgen Inc Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Amgen Inc Recent Developments/Updates
2.7 Pfizer Inc.
2.7.1 Pfizer Inc. Details
2.7.2 Pfizer Inc. Major Business
2.7.3 Pfizer Inc. Membranous Nephropathy Treatment Product and Services
2.7.4 Pfizer Inc. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Pfizer Inc. Recent Developments/Updates
2.8 Novartis. AG.
2.8.1 Novartis. AG. Details
2.8.2 Novartis. AG. Major Business
2.8.3 Novartis. AG. Membranous Nephropathy Treatment Product and Services
2.8.4 Novartis. AG. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Novartis. AG. Recent Developments/Updates
2.9 Apotex Inc.
2.9.1 Apotex Inc. Details
2.9.2 Apotex Inc. Major Business
2.9.3 Apotex Inc. Membranous Nephropathy Treatment Product and Services
2.9.4 Apotex Inc. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Apotex Inc. Recent Developments/Updates
2.10 Teva Pharma Industries Ltd.
2.10.1 Teva Pharma Industries Ltd. Details
2.10.2 Teva Pharma Industries Ltd. Major Business
2.10.3 Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Product and Services
2.10.4 Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Teva Pharma Industries Ltd. Recent Developments/Updates
3 Competitive Environment: Membranous Nephropathy Treatment by Manufacturer
3.1 Global Membranous Nephropathy Treatment Sales Quantity by Manufacturer (2018-2023)
3.2 Global Membranous Nephropathy Treatment Revenue by Manufacturer (2018-2023)
3.3 Global Membranous Nephropathy Treatment Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Membranous Nephropathy Treatment by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Membranous Nephropathy Treatment Manufacturer Market Share in 2022
3.4.2 Top 6 Membranous Nephropathy Treatment Manufacturer Market Share in 2022
3.5 Membranous Nephropathy Treatment Market: Overall Company Footprint Analysis
3.5.1 Membranous Nephropathy Treatment Market: Region Footprint
3.5.2 Membranous Nephropathy Treatment Market: Company Product Type Footprint
3.5.3 Membranous Nephropathy Treatment Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Membranous Nephropathy Treatment Market Size by Region
4.1.1 Global Membranous Nephropathy Treatment Sales Quantity by Region (2018-2029)
4.1.2 Global Membranous Nephropathy Treatment Consumption Value by Region (2018-2029)
4.1.3 Global Membranous Nephropathy Treatment Average Price by Region (2018-2029)
4.2 North America Membranous Nephropathy Treatment Consumption Value (2018-2029)
4.3 Europe Membranous Nephropathy Treatment Consumption Value (2018-2029)
4.4 Asia-Pacific Membranous Nephropathy Treatment Consumption Value (2018-2029)
4.5 South America Membranous Nephropathy Treatment Consumption Value (2018-2029)
4.6 Middle East and Africa Membranous Nephropathy Treatment Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
5.2 Global Membranous Nephropathy Treatment Consumption Value by Type (2018-2029)
5.3 Global Membranous Nephropathy Treatment Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
6.2 Global Membranous Nephropathy Treatment Consumption Value by Application (2018-2029)
6.3 Global Membranous Nephropathy Treatment Average Price by Application (2018-2029)
7 North America
7.1 North America Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
7.2 North America Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
7.3 North America Membranous Nephropathy Treatment Market Size by Country
7.3.1 North America Membranous Nephropathy Treatment Sales Quantity by Country (2018-2029)
7.3.2 North America Membranous Nephropathy Treatment Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
8.2 Europe Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
8.3 Europe Membranous Nephropathy Treatment Market Size by Country
8.3.1 Europe Membranous Nephropathy Treatment Sales Quantity by Country (2018-2029)
8.3.2 Europe Membranous Nephropathy Treatment Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Membranous Nephropathy Treatment Market Size by Region
9.3.1 Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Membranous Nephropathy Treatment Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
10.2 South America Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
10.3 South America Membranous Nephropathy Treatment Market Size by Country
10.3.1 South America Membranous Nephropathy Treatment Sales Quantity by Country (2018-2029)
10.3.2 South America Membranous Nephropathy Treatment Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Membranous Nephropathy Treatment Market Size by Country
11.3.1 Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Membranous Nephropathy Treatment Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Membranous Nephropathy Treatment Market Drivers
12.2 Membranous Nephropathy Treatment Market Restraints
12.3 Membranous Nephropathy Treatment Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Membranous Nephropathy Treatment and Key Manufacturers
13.2 Manufacturing Costs Percentage of Membranous Nephropathy Treatment
13.3 Membranous Nephropathy Treatment Production Process
13.4 Membranous Nephropathy Treatment Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Membranous Nephropathy Treatment Typical Distributors
14.3 Membranous Nephropathy Treatment Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
Table 1. Global Membranous Nephropathy Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Membranous Nephropathy Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Abbie. Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Abbie. Inc. Major Business
Table 5. Abbie. Inc. Membranous Nephropathy Treatment Product and Services
Table 6. Abbie. Inc. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Abbie. Inc. Recent Developments/Updates
Table 8. Astrazeneca Plc. Basic Information, Manufacturing Base and Competitors
Table 9. Astrazeneca Plc. Major Business
Table 10. Astrazeneca Plc. Membranous Nephropathy Treatment Product and Services
Table 11. Astrazeneca Plc. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Astrazeneca Plc. Recent Developments/Updates
Table 13. F. Hoffman- La Roche Ltd. Basic Information, Manufacturing Base and Competitors
Table 14. F. Hoffman- La Roche Ltd. Major Business
Table 15. F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Product and Services
Table 16. F. Hoffman- La Roche Ltd. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. F. Hoffman- La Roche Ltd. Recent Developments/Updates
Table 18. Fibrogen Basic Information, Manufacturing Base and Competitors
Table 19. Fibrogen Major Business
Table 20. Fibrogen Membranous Nephropathy Treatment Product and Services
Table 21. Fibrogen Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Fibrogen Recent Developments/Updates
Table 23. Allergan Plc. Basic Information, Manufacturing Base and Competitors
Table 24. Allergan Plc. Major Business
Table 25. Allergan Plc. Membranous Nephropathy Treatment Product and Services
Table 26. Allergan Plc. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Allergan Plc. Recent Developments/Updates
Table 28. Amgen Inc Basic Information, Manufacturing Base and Competitors
Table 29. Amgen Inc Major Business
Table 30. Amgen Inc Membranous Nephropathy Treatment Product and Services
Table 31. Amgen Inc Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Amgen Inc Recent Developments/Updates
Table 33. Pfizer Inc. Basic Information, Manufacturing Base and Competitors
Table 34. Pfizer Inc. Major Business
Table 35. Pfizer Inc. Membranous Nephropathy Treatment Product and Services
Table 36. Pfizer Inc. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Pfizer Inc. Recent Developments/Updates
Table 38. Novartis. AG. Basic Information, Manufacturing Base and Competitors
Table 39. Novartis. AG. Major Business
Table 40. Novartis. AG. Membranous Nephropathy Treatment Product and Services
Table 41. Novartis. AG. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Novartis. AG. Recent Developments/Updates
Table 43. Apotex Inc. Basic Information, Manufacturing Base and Competitors
Table 44. Apotex Inc. Major Business
Table 45. Apotex Inc. Membranous Nephropathy Treatment Product and Services
Table 46. Apotex Inc. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 47. Apotex Inc. Recent Developments/Updates
Table 48. Teva Pharma Industries Ltd. Basic Information, Manufacturing Base and Competitors
Table 49. Teva Pharma Industries Ltd. Major Business
Table 50. Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Product and Services
Table 51. Teva Pharma Industries Ltd. Membranous Nephropathy Treatment Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 52. Teva Pharma Industries Ltd. Recent Developments/Updates
Table 53. Global Membranous Nephropathy Treatment Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 54. Global Membranous Nephropathy Treatment Revenue by Manufacturer (2018-2023) & (USD Million)
Table 55. Global Membranous Nephropathy Treatment Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 56. Market Position of Manufacturers in Membranous Nephropathy Treatment, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 57. Head Office and Membranous Nephropathy Treatment Production Site of Key Manufacturer
Table 58. Membranous Nephropathy Treatment Market: Company Product Type Footprint
Table 59. Membranous Nephropathy Treatment Market: Company Product Application Footprint
Table 60. Membranous Nephropathy Treatment New Market Entrants and Barriers to Market Entry
Table 61. Membranous Nephropathy Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 62. Global Membranous Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 63. Global Membranous Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 64. Global Membranous Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 65. Global Membranous Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 66. Global Membranous Nephropathy Treatment Average Price by Region (2018-2023) & (US$/Unit)
Table 67. Global Membranous Nephropathy Treatment Average Price by Region (2024-2029) & (US$/Unit)
Table 68. Global Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 69. Global Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 70. Global Membranous Nephropathy Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Global Membranous Nephropathy Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Global Membranous Nephropathy Treatment Average Price by Type (2018-2023) & (US$/Unit)
Table 73. Global Membranous Nephropathy Treatment Average Price by Type (2024-2029) & (US$/Unit)
Table 74. Global Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 75. Global Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 76. Global Membranous Nephropathy Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 77. Global Membranous Nephropathy Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 78. Global Membranous Nephropathy Treatment Average Price by Application (2018-2023) & (US$/Unit)
Table 79. Global Membranous Nephropathy Treatment Average Price by Application (2024-2029) & (US$/Unit)
Table 80. North America Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 81. North America Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 82. North America Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 83. North America Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 84. North America Membranous Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 85. North America Membranous Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 86. North America Membranous Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 87. North America Membranous Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Europe Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 89. Europe Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 90. Europe Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 91. Europe Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 92. Europe Membranous Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 93. Europe Membranous Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 94. Europe Membranous Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 95. Europe Membranous Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 96. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 97. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 98. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 99. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 100. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 101. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 102. Asia-Pacific Membranous Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 103. Asia-Pacific Membranous Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 104. South America Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 105. South America Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 106. South America Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 107. South America Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 108. South America Membranous Nephropathy Treatment Sales Quantity by Country (2018-2023) & (K Units)
Table 109. South America Membranous Nephropathy Treatment Sales Quantity by Country (2024-2029) & (K Units)
Table 110. South America Membranous Nephropathy Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 111. South America Membranous Nephropathy Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 112. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Type (2018-2023) & (K Units)
Table 113. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Type (2024-2029) & (K Units)
Table 114. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Application (2018-2023) & (K Units)
Table 115. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Application (2024-2029) & (K Units)
Table 116. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Region (2018-2023) & (K Units)
Table 117. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity by Region (2024-2029) & (K Units)
Table 118. Middle East & Africa Membranous Nephropathy Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 119. Middle East & Africa Membranous Nephropathy Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 120. Membranous Nephropathy Treatment Raw Material
Table 121. Key Manufacturers of Membranous Nephropathy Treatment Raw Materials
Table 122. Membranous Nephropathy Treatment Typical Distributors
Table 123. Membranous Nephropathy Treatment Typical Customers
List of Figures
Figure 1. Membranous Nephropathy Treatment Picture
Figure 2. Global Membranous Nephropathy Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Membranous Nephropathy Treatment Consumption Value Market Share by Type in 2022
Figure 4. Alkylating Agents Examples
Figure 5. Cyclophosphamide Examples
Figure 6. Chlorambucil Examples
Figure 7. Cyclic Peptides Examples
Figure 8. Tacrolimus Examples
Figure 9. MycophenolateMofetil Examples
Figure 10. Others Examples
Figure 11. Global Membranous Nephropathy Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 12. Global Membranous Nephropathy Treatment Consumption Value Market Share by Application in 2022
Figure 13. Hospital pharmacy Examples
Figure 14. Retail pharmacy Examples
Figure 15. Online Pharmacy Examples
Figure 16. Global Membranous Nephropathy Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 17. Global Membranous Nephropathy Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 18. Global Membranous Nephropathy Treatment Sales Quantity (2018-2029) & (K Units)
Figure 19. Global Membranous Nephropathy Treatment Average Price (2018-2029) & (US$/Unit)
Figure 20. Global Membranous Nephropathy Treatment Sales Quantity Market Share by Manufacturer in 2022
Figure 21. Global Membranous Nephropathy Treatment Consumption Value Market Share by Manufacturer in 2022
Figure 22. Producer Shipments of Membranous Nephropathy Treatment by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 23. Top 3 Membranous Nephropathy Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 24. Top 6 Membranous Nephropathy Treatment Manufacturer (Consumption Value) Market Share in 2022
Figure 25. Global Membranous Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 26. Global Membranous Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)
Figure 27. North America Membranous Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Europe Membranous Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)
Figure 29. Asia-Pacific Membranous Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)
Figure 30. South America Membranous Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)
Figure 31. Middle East & Africa Membranous Nephropathy Treatment Consumption Value (2018-2029) & (USD Million)
Figure 32. Global Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 33. Global Membranous Nephropathy Treatment Consumption Value Market Share by Type (2018-2029)
Figure 34. Global Membranous Nephropathy Treatment Average Price by Type (2018-2029) & (US$/Unit)
Figure 35. Global Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 36. Global Membranous Nephropathy Treatment Consumption Value Market Share by Application (2018-2029)
Figure 37. Global Membranous Nephropathy Treatment Average Price by Application (2018-2029) & (US$/Unit)
Figure 38. North America Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 39. North America Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 40. North America Membranous Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 41. North America Membranous Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)
Figure 42. United States Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 43. Canada Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 44. Mexico Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. Europe Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 46. Europe Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 47. Europe Membranous Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 48. Europe Membranous Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)
Figure 49. Germany Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. France Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 51. United Kingdom Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 52. Russia Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 53. Italy Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 55. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 56. Asia-Pacific Membranous Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 57. Asia-Pacific Membranous Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)
Figure 58. China Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Japan Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. Korea Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 61. India Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 62. Southeast Asia Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 63. Australia Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. South America Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 65. South America Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 66. South America Membranous Nephropathy Treatment Sales Quantity Market Share by Country (2018-2029)
Figure 67. South America Membranous Nephropathy Treatment Consumption Value Market Share by Country (2018-2029)
Figure 68. Brazil Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 69. Argentina Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity Market Share by Type (2018-2029)
Figure 71. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity Market Share by Application (2018-2029)
Figure 72. Middle East & Africa Membranous Nephropathy Treatment Sales Quantity Market Share by Region (2018-2029)
Figure 73. Middle East & Africa Membranous Nephropathy Treatment Consumption Value Market Share by Region (2018-2029)
Figure 74. Turkey Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 75. Egypt Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 76. Saudi Arabia Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 77. South Africa Membranous Nephropathy Treatment Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 78. Membranous Nephropathy Treatment Market Drivers
Figure 79. Membranous Nephropathy Treatment Market Restraints
Figure 80. Membranous Nephropathy Treatment Market Trends
Figure 81. Porters Five Forces Analysis
Figure 82. Manufacturing Cost Structure Analysis of Membranous Nephropathy Treatment in 2022
Figure 83. Manufacturing Process Analysis of Membranous Nephropathy Treatment
Figure 84. Membranous Nephropathy Treatment Industrial Chain
Figure 85. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 86. Direct Channel Pros & Cons
Figure 87. Indirect Channel Pros & Cons
Figure 88. Methodology
Figure 89. Research Process and Data Source
| 【膜性腎症治療について】 ※膜性腎症は、腎臓の糸球体における障害を特徴とする疾患であり、特に成人において比較的多く見られる疾患です。この病気は、主に免疫系の異常に起因しており、糸球体基底膜に免疫複合体が沈着することで炎症やフィブリン沈着を引き起こします。これにより、腎臓の濾過機能が低下し、蛋白尿や浮腫、高血圧等の症状が現れることがあります。 膜性腎症の特徴としては、まず第一に弥漫性の糸球体の基底膜の肥厚が挙げられます。この肥厚は、主に感染、悪性腫瘍、自身の免疫疾患、または薬剤に起因する場合があります。特に、原発性の膜性腎症は、腎臓に特異的な自己免疫反応が関与し、抗PLA2R抗体の出現が示されることが多いです。さらに、二次性膜性腎症は、基礎となる疾患の治療によって改善される可能性があります。 膜性腎症には、いくつかの種類があります。原発性膜性腎症のほかに、二次性膜性腎症と呼ばれるものがあります。二次性膜性腎症は、他の疾患や状態によって引き起こされるものです。この場合、リウマチ性疾患、ウイルス感染（例えばB型肝炎やC型肝炎）、あるいはがん（特に肺がんやリンパ腫など）が関連していることがあります。原発性と二次性の区別は治療方針や予後に影響を与えるため、診断時の注意が必要です。 治療においては、膜性腎症の治療は個別化されることが重要です。たとえば、軽度の症状や初期段階では観察だけを行うことがあり、特に腎機能が安定している場合には、治療を急ぐ必要がないことがあります。しかし、重度の蛋白尿や腎機能の低下が見られる場合、治療が必要です。 治療方法としては、ステロイド薬や免疫抑制剤が一般的に用いられます。ステロイド薬は、免疫反応を抑制することで、基底膜に沈着した免疫複合体の処理や炎症の軽減に寄与します。また、シクロフォスファミドやミコフェノール酸モフェチルなどの免疫抑制剤も併用されることがあります。これらの薬剤は、病気の進行を遅らせ、腎機能を保護する役割を果たします。 さらに、最近では、抗PLA2R抗体に対するモノクローナル抗体治療や、補体介在性の治療法（例えば、補体を抑制する薬剤）の研究が進んでいます。これにより、より効果的な治療法の確立が期待されています。ちなみに、膜性腎症に対する新しい治療法についての研究も進行中であり、さまざまなアプローチが探求されています。 膜性腎症の治療においては、患者の全体的な健康状態や、潜在的な合併症の有無、ならびに患者の生活の質を考慮することが重要です。たとえば、高血圧の管理は、膜性腎症の患者において特に重要であり、降圧薬の使用が推奨されることがあります。また、食事制限や生活習慣の改善も浮腫の軽減に繋がるため、患者の教育が重要です。 膜性腎症の早期診断と治療は、最終的な予後に大きな影響を与えるため、定期的なフォローアップも不可欠です。患者には、尿検査や血液検査を行い、腎機能や蛋白尿の状態を定期的に評価することが求められます。 膜性腎症に関連する技術として、腎生検が挙げられます。腎生検は、正確な診断と原因の特定に必要な手技であり、糸球体の構造や炎症の程度を評価するために用いられます。この結果をもとに治療方針を決定することが可能です。また、最新の技術として、バイオマーカーやジェノム解析の情報を活用することで、より個別化された治療が進展することが期待されます。 膜性腎症は、単なる腎疾患にとどまらず、全身的な健康状態にも影響を与えるため、包括的なアプローチが必要です。患者の心理的サポートや栄養指導、日常生活の管理など、医療従事者との連携を強化しながら、患者自身も治療に積極的に関与することが求められます。これにより、より良い治療成績を得られる可能性が高まります。 最後に、膜性腎症に関する研究は今後も進められる必要があります。新しい治療戦略の発見や、病態の解明により、疾患の理解が深まり、これまで難治とされてきた患者に対してもより効果的な治療法の提供が可能になるでしょう。これらの進展が、膜性腎症患者の生活の質の向上に繋がることが期待されます。 |
